Gabe Brier is Of Counsel in Quinn Emanuel’s New York office. Gabe focuses his practice on patent actions in the pharmaceutical, biotechnology and chemical arts. He has represented major and emerging corporations in patent infringement actions regarding pharmaceutical compounds, drug delivery systems, methods of disease treatment and medical devices. Gabe has participated in all aspects of patent litigation, including pre-suit investigation, trial, and appeal.
His recent representations include litigations concerning: Pomalyst® (a treatment for multiple myeloma); Revlimid® (a treatment for multiple myeloma and myelodysplastic syndromes); Thalomid® (a treatment for multiple myeloma and erythema nodosum leprosum); Xyrem® (a treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy); Qsymia® (a treatment for chronic weight management); and Letairis® (a treatment for pulmonary arterial hypertension).
Mr. Brier’s practice also includes counseling clients regarding regulatory issues, patent portfolio evaluation, including conducting due diligence investigations regarding the patentability of inventions, the validity of patents, and the freedom to operate new technologies. His practice also involves the negotiation and preparation of licensing and settlement agreements.
- Georgetown University
- Columbia University
(B.S., Chemical Engineering, 1998)
- Jones Day:
- Associate, 2004 – 2012